2019
Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma
Guerra MT, Florentino RM, Franca A, Lima Filho AC, Dos Santos ML, Fonseca RC, Lemos FO, Fonseca MC, Kruglov E, Mennone A, Njei B, Gibson J, Guan F, Cheng YC, Ananthanarayanan M, Gu J, Jiang J, Zhao H, Lima CX, Vidigal PT, Oliveira AG, Nathanson MH, Leite MF. Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma. Gut 2019, 68: 1676. PMID: 31315892, PMCID: PMC7087395, DOI: 10.1136/gutjnl-2018-317811.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsApoptosisCalcium SignalingCarcinogenesisCarcinoma, HepatocellularCell ProliferationCells, CulturedDNA MethylationFemaleGene Expression Regulation, NeoplasticHepatocytesHumansInositol 1,4,5-Trisphosphate ReceptorsLiverLiver NeoplasmsLiver RegenerationMaleMice, KnockoutMiddle AgedSurvival AnalysisConceptsChronic liver diseaseITPR3 expressionLiver cancer cellsLiver diseaseMouse modelFinal common eventCancer cellsSpecimens of patientsIndependent patient cohortsControl liver specimensHuman HCC cellsType 3 InsP3 receptorHuman liver samplesIncreased expression levelCancer deathPatient cohortCommon molecular eventPoor survivalHepatocellular carcinomaLiver specimensNormal liverHCC cellsAbstractTextHCCType 3 isoformImpact of Bariatric Surgery on Outcomes of Patients with Sickle Cell Disease: a Nationwide Inpatient Sample Analysis, 2004–2014
Sharma P, McCarty TR, Yadav S, Ngu JN, Njei B. Impact of Bariatric Surgery on Outcomes of Patients with Sickle Cell Disease: a Nationwide Inpatient Sample Analysis, 2004–2014. Obesity Surgery 2019, 29: 1789-1796. PMID: 30805858, DOI: 10.1007/s11695-019-03780-0.Peer-Reviewed Original ResearchConceptsSickle cell diseaseVaso-occlusive crisisAcute chest syndromeBariatric surgeryIncidence risk ratioChest syndromeMorbid obesityClinical outcomesHospitalization costsCell diseaseUnited States Nationwide Inpatient Sample databaseNationwide Inpatient Sample databaseOutcomes of patientsMulti-organ failureSurgery-related complicationsHigher hospitalization costsUrinary tract infectionWeight loss surgeryDisease-specific treatmentLength of staySickle cell patientsHospital mortalityRespiratory failureThromboembolic eventsConclusionsBariatric surgeryEffects of Endotoxin on Type 3 Inositol 1,4,5‐Trisphosphate Receptor in Human Cholangiocytes
Franca A, Filho A, Guerra MT, Weerachayaphorn J, dos Santos M, Njei B, Robert M, Lima C, Vidigal P, Banales JM, Ananthanarayanan M, Leite MF, Nathanson MH. Effects of Endotoxin on Type 3 Inositol 1,4,5‐Trisphosphate Receptor in Human Cholangiocytes. Hepatology 2019, 69: 817-830. PMID: 30141207, PMCID: PMC6351171, DOI: 10.1002/hep.30228.Peer-Reviewed Original ResearchConceptsToll-like receptor 4Alcoholic hepatitisEffect of endotoxinBile duct cellsNF-κBInhibition of TLR4Human cholangiocytesStimulation of TLR4Duct cellsSevere alcoholic hepatitisCholestasis of sepsisForms of cholestasisNF-κB subunitsP65/p50Trisphosphate receptorReceptor 4Clinical conditionsBicarbonate secretionHepatocellular changesITPR3 expressionCholestasisType 3 inositolLPS receptorAgonist stimulusSepsisNational Trends in Use of Opioid Drugs Among Cirrhosis-related Hospitalizations in the United States, 2004 to 2012
McCarty TR, Haque L, Njei B. National Trends in Use of Opioid Drugs Among Cirrhosis-related Hospitalizations in the United States, 2004 to 2012. Journal Of Clinical Gastroenterology 2019, 53: 78-79. PMID: 27984400, DOI: 10.1097/mcg.0000000000000771.Peer-Reviewed Original Research
2018
Cannabis Use Is Associated With Increased Risk of Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Njei B, Sharma P, McCarty TR, Singh M, Haque L, Aslanian HR, Jamidar P, Muniraj T. Cannabis Use Is Associated With Increased Risk of Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Pancreas 2018, 47: 1142-1149. PMID: 30134357, DOI: 10.1097/mpa.0000000000001143.Peer-Reviewed Original ResearchConceptsPost-endoscopic retrograde cholangiopancreatography pancreatitisIncidence risk ratioCholangiopancreatography pancreatitisCannabis useRisk of PEPEndoscopic retrograde cholangiopancreatography pancreatitisUS Nationwide Inpatient SampleRate of PEPShorter hospital stayNationwide Inpatient SampleNinth Edition codesImpact of cannabisPoisson regression modelsHospital deathHospital stayIndependent predictorsEdition codesRisk ratioInpatient SampleInternational ClassificationMultivariate analysisPancreatitisPatientsCannabisSignificant increaseImpact of bariatric surgery in patients with HIV infection
Sharma P, McCarty TR, Ngu JN, O'Donnell M, Njei B. Impact of bariatric surgery in patients with HIV infection. AIDS 2018, 32: 1959-1965. PMID: 30157083, PMCID: PMC6126912, DOI: 10.1097/qad.0000000000001915.Peer-Reviewed Original ResearchConceptsBariatric surgeryIncidence risk ratioMorbid obesityRespiratory failureObese patientsRenal failureClinical outcomesUnited States Nationwide Inpatient Sample databaseNationwide Inpatient Sample databaseObese HIV patientsLife-threatening morbidityUrinary tract infectionWeight loss surgeryRelevant clinical outcomesLength of stayRates of obesityHospital mortalityHIV patientsThromboembolic eventsSecondary outcomesTract infectionsHIV infectionPrimary outcomeMultivariable analysisDischarge diagnosis
2017
Impact of Bariatric Surgery on Outcomes of Patients with Inflammatory Bowel Disease: a Nationwide Inpatient Sample Analysis, 2004–2014
Sharma P, McCarty TR, Njei B. Impact of Bariatric Surgery on Outcomes of Patients with Inflammatory Bowel Disease: a Nationwide Inpatient Sample Analysis, 2004–2014. Obesity Surgery 2017, 28: 1015-1024. PMID: 29047047, DOI: 10.1007/s11695-017-2959-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBariatric SurgeryDatabases, FactualFemaleHospital CostsHospital MortalityHospitalizationHumansIncidenceInflammatory Bowel DiseasesInpatientsMaleMiddle AgedMorbidityObesity, MorbidPostoperative ComplicationsPrognosisTreatment OutcomeUnited StatesYoung AdultConceptsInflammatory bowel diseaseIncidence risk ratioObese IBD patientsBariatric surgeryMorbid obesityIBD patientsRenal failureBowel diseaseClinical outcomesUnited States National Inpatient Sample (NIS) databaseNational Inpatient Sample databaseOutcomes of patientsLength of stayPaucity of dataHospital mortalityThromboembolic eventsObese patientsSecondary outcomesHospitalized patientsPrimary outcomeMultivariable analysisDischarge diagnosisFistula formationHospitalization costsRisk ratioSurvival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease
Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2017, 46: 1061-1069. PMID: 28960360, DOI: 10.1111/apt.14342.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseFatty liver diseaseLarger tumor sizeLiver diseaseHCC etiologyCurative intentNAFLD-HCCCurative treatmentTumor sizeMetastatic HCCCardiovascular diseaseHepatocellular carcinomaDecompensated liver diseaseWorse median survivalAbsence of cirrhosisSignificant survival differenceDiagnosis of HCCLess cirrhosisNAFLD groupMedian survivalWorse survivalFavorable survivalIndependent predictorsLiver cirrhosisHCC groupEarly transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding
Njei B, McCarty TR, Laine L. Early transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding. Journal Of Gastroenterology And Hepatology 2017, 32: 852-858. PMID: 27624167, PMCID: PMC5350067, DOI: 10.1111/jgh.13593.Peer-Reviewed Original ResearchConceptsEarly transjugular intrahepatic portosystemic shuntTransjugular intrahepatic portosystemic shuntAcute esophageal variceal bleedingEsophageal variceal bleedingIntrahepatic portosystemic shuntVariceal bleedingUS patientsPortosystemic shuntNationwide Inpatient Sample databaseHospital mortality rateUS clinical practiceDays of hospitalizationFurther bleedingHospital deathRecurrent bleedingEndoscopic therapyInpatient mortalityPreventive therapySecondary outcomesHepatic encephalopathyPrimary outcomeHigh riskHospital reductionMortality ratePatientsVanishing bile duct syndrome in Hodgkin’s lymphoma: A case report and literature review
Bakhit M, McCarty TR, Park S, Njei B, Cho M, Karagozian R, Liapakis A. Vanishing bile duct syndrome in Hodgkin’s lymphoma: A case report and literature review. World Journal Of Gastroenterology 2017, 23: 366-372. PMID: 28127210, PMCID: PMC5236516, DOI: 10.3748/wjg.v23.i2.366.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic AgentsBile Duct DiseasesBile Ducts, IntrahepaticBiopsyCholangiopancreatography, Magnetic ResonanceCholestasisExomeHepatocyte Growth FactorHigh-Throughput Nucleotide SequencingHodgkin DiseaseHumansHyperbilirubinemiaHypertension, PortalJaundiceLiverLiver Function TestsMaleNeoplasm StagingProto-Oncogene ProteinsSyndromeTomography, X-Ray ComputedConceptsBile duct syndromeHodgkin's lymphomaIntra-hepatic bile ductsBile duct lossBile duct injuryAdverse drug reactionsDifferent pathologic conditionsTransplant evaluationDuct injuryAllograft rejectionClinical recoveryParaneoplastic phenomenonBiliary cirrhosisLiver biopsyLiver failureBile ductAutoimmune diseasesCase reportDrug reactionsEarly recognitionPhysical examPoor responseVBDSHumoral factorsMedical treatment
2016
Vanishing Bile Duct Syndrome in Hodgkin’s Lymphoma
Bakhit M, McCarty TR, Park S, Njei B, Cho M, Karagozian R, Liapakis A. Vanishing Bile Duct Syndrome in Hodgkin’s Lymphoma. Journal Of Clinical Gastroenterology 2016, 50: 688. PMID: 27203429, PMCID: PMC4980195, DOI: 10.1097/mcg.0000000000000548.Peer-Reviewed Original ResearchPrevalence of hepatitis delta infection in the United States: National Health and Nutrition Examination Survey, 1999‐2012
Njei B, Do A, Lim JK. Prevalence of hepatitis delta infection in the United States: National Health and Nutrition Examination Survey, 1999‐2012. Hepatology 2016, 64: 681-682. PMID: 26453027, PMCID: PMC4826621, DOI: 10.1002/hep.28279.Peer-Reviewed Original Research